BioVersys receives US FDA nod to recruit US patients for BV100 HABP/VABP phase 3 trial to treat hospital-acquired or ventilator-associated bacterial pneumonia: Basel, Switzerland ...
The antibiotics are needed to combat key drug-resistant bacteria causing severe bloodstream and urinary tract infections, ...
Race for new antibiotics intensifies as WHO warns drug pipeline remains thin, and remains structurally unfit to support ...
Ad hoc announcement pursuant to Art. 53 LR BV100 is a potential best-in-class anti-infective agent in treating hospital-acquired bacterial ...
Drugmakers must focus on developing new antibiotics to fight hospital “superbugs” including meningitis and other infections ...
WHO’s director of antimicrobial resistance, Dr Yvan Hutin, says science needs to catch up with drug-resistant bacteria.
Beyond Cancer, Ltd., a clinical stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an investigational immunotherapeutic for solid tumors and subsidiary of Beyond Air ...
We need a reliable pipeline with new antibacterial agents that are innovative, affordable, accessible to all those who need them. Dr Yvan Hutin/ ...
In a landmark public health initiative, Bangladesh launched a nationwide Typhoid Conjugate Vaccine (TCV) campaign in October ...
EL MUNDO on MSN
The use of certain antibiotics leaves a mark on the intestinal microbiota that lasts between four and eight years after taking them
A study of about 15,000 adults finds a lasting association between the use of certain antibiotics and the balance of the ...
Amid continuing challenges for companies developing antibiotics, a new report highlights some bright spots in efforts to ...
Health and Me on MSN
WHO's new guidance to accelerate antibiotics development for 3 deadly bacterial infections
As per WHO data, AMR is an urgent global public health threat, killing at least 1.27 million people worldwide and associated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results